NAD-boosting treatment shows no Parkinson's benefit in yearlong trial

A large objective proceedings involving 410 radical with aboriginal Parkinson's illness has recovered nary objective payment from nicotinamide riboside (NR), a compound that increases cellular levels of nicotinamide adenine dinucleotide (NAD). The findings are published successful JAMA.